| Literature DB >> 34615932 |
Jarrett D Morrow1, Peter J Castaldi2, Robert P Chase2, Jeong H Yun2, Sool Lee2, Yang-Yu Liu2, Craig P Hersh2,3.
Abstract
The human microbiome has a role in the development of multiple diseases. Individual microbiome profiles are highly personalized, though many species are shared. Understanding the relationship between the human microbiome and disease may inform future individualized treatments. We hypothesize the blood microbiome signature may be a surrogate for some lung microbial characteristics. We sought associations between the blood microbiome signature and lung-relevant host factors. Based on reads not mapped to the human genome, we detected microbial nucleic acids through secondary use of peripheral blood RNA-sequencing from 2,590 current and former smokers with and without chronic obstructive pulmonary disease (COPD) from the COPDGene study. We used the Genome Analysis Toolkit (GATK) microbial pipeline PathSeq to infer microbial profiles. We tested associations between the inferred profiles and lung disease relevant phenotypes and examined links to host gene expression pathways. We replicated our analyses using a second independent set of blood RNA-seq data from 1,065 COPDGene study subjects and performed a meta-analysis across the two studies. The four phyla with highest abundance across all subjects were Proteobacteria, Actinobacteria, Firmicutes and Bacteroidetes. In our meta-analysis, we observed associations (q-value < 0.05) between Acinetobacter, Serratia, Streptococcus and Bacillus inferred abundances and Modified Medical Research Council (mMRC) dyspnea score. Current smoking status was associated (q < 0.05) with Acinetobacter, Serratia and Cutibacterium abundance. All 12 taxa investigated were associated with at least one white blood cell distribution variable. Abundance for nine of the 12 taxa was associated with sex, and seven of the 12 taxa were associated with race. Host-microbiome interaction analysis revealed clustering of genera associated with mMRC dyspnea score and smoking status, through shared links to several host pathways. This study is the first to identify a bacterial microbiome signature in the peripheral blood of current and former smokers. Understanding the relationships between systemic microbial signatures and lung-related phenotypes may inform novel interventions and aid understanding of the systemic effects of smoking.Entities:
Mesh:
Year: 2021 PMID: 34615932 PMCID: PMC8494912 DOI: 10.1038/s41598-021-99238-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
COPDGene study subjects.
| Demographics | N = 2590 |
|---|---|
| Age, years | 65.5 ± 8.6 |
| Sex (Female/Male) | 1257/1333 |
| Race (Non-Hispanic White/African American) | 1940/650 |
| Smoking status (Current/Former) (n = 2580) | 909/1671 |
| Smoking History, pack-years (n = 2579) | 44.0 ± 24.0 |
| 4 | 101 |
| 3 | 245 |
| 2 | 505 |
| 1 | 258 |
| Control | 1101 |
| PRISm * | 331 |
| FEV1% predicted (n = 2541) | 78.6 ± 24.2 |
| FEV1/FVC (n = 2540) | 0.68 ± 0.15 |
| Percent emphysema at -950HU (n = 2388) | 5.5 ± 9.2 |
| Body mass index kg/m2 (n = 2581) | 29.0 ± 6.3 |
| Airway wall thickness, segmental bronchi (n = 2385) | 1.03 ± 0.22 |
| Severe exacerbation in the year prior ** (no/yes) (n = 2581) | 2367/214 |
| Treated with chronic oral corticosteroids (no/yes) (n = 2538) | 2504/34 |
| Survival (alive/deceased) *** | 2431/159 |
| 0 | 1316 |
| 1 | 344 |
| 2 | 315 |
| 3 | 424 |
| 4 | 182 |
| 6-min walk distance ft (n = 2539) | 1311 ± 442 |
| Comorbidity score **** (range 0 to 14) (n = 2581) | 2.97 ± 1.98 |
FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PRISm = Preserved Ratio Impaired Spirometry; mMRC = Modified Medical Research Council dyspnea score.
*PRISm (FEV1 < 80% predicted with FEV1/FVC ≥ 0.7)[38].
**Emergency department or hospital admission.
***Survival status as of October 2018.
****Sum of comorbidities reported, considering Coronary Heart disease, Diabetes, Congestive heart failure, Stroke, Osteoarthritis, Osteoporosis, Hypertension, High cholesterol, Gastroesophageal reflux disease, Stomach ulcers, Obesity, Sleep apnea, Hay fever, Peripheral Vascular Disease[53].
Figure 1Overview of the study design illustrating the sequencing, statistical and gene enrichment framework. This illustrates the integration with host characteristics and gene expression for observations of host microbiome interaction (GATK = Genome Analysis Toolkit; MaAsLin2 = Multivariate Association with Linear Models).
Figure 2Heatmap of the associations between genera inferred abundance and host-related variables for the meta-analysis. Variables with at least one finding with FDR < 10% were included. The value in each cell is the adjusted q-value. The color scale for the cells represents the sign of the effect multiplied by negative log10 of the q-values, with intensity proportional to significance and gray shading representing positively correlated associations and blue shading representing negatively correlated associations. Results with discordant directions of effect in the meta-analysis are set to q = 1 (white) (heatmap produced using the labeledHeatmap function from the R package WGCNA[45]). Variables with at least one significant association are included (WBC = white blood cell count, Lymphocytes = lymphocyte count, NeutroLymph_Ratio = ratio of neutrophil counts to lymphocyte counts, Lymphocyte_pct = percentage of lymphocytes, Neutrophil_pct = percentage of neutrophils, 6 MW = six-minute walk distance, mMRC = Modified Medical Research Council dyspnea score, COPD (case–control) = COPD cases vs. controls, PackYears = pack-years history of smoking, Smoking (current-former) = current vs. former smoking status).
Figure 3Community from the bipartite network from the host-microbiome interaction analysis with relevance to COPD, dyspnea and smoking associations. Edges represent a significant (FDR < 5%) association between genus abundance (blue circles) and the expression of the human Hallmark pathway (red squares) in the meta-analysis (figure produced using the R package igraph[52]).
| Clinical center | Institution title | Protocol number |
|---|---|---|
| National Jewish Health | National Jewish IRB | HS-1883a |
| Brigham and Women’s Hospital | Partners Human Research Committee | 2007-P-000554/2; BWH |
| Baylor College of Medicine | Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals | H-22209 |
| Michael E. DeBakey VAMC | Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals | H-22202 |
| Columbia University Medical Center | Columbia University Medical Center IRB | IRB-AAAC9324 |
| Duke University Medical Center | The Duke University Health System Institutional Review Board for Clinical Investigations (DUHS IRB) | Pro00004464 |
| Johns Hopkins University | Johns Hopkins Medicine Institutional Review Boards (JHM IRB) | NA_00011524 |
| Los Angeles Biomedical Research Institute | The John F. Wolf, MD Human Subjects Committee of Harbor-UCLA Medical Center | 12756–01 |
| Morehouse School of Medicine | Morehouse School of Medicine Institutional Review Board | 07–1029 |
| Temple University | Temple University Office for Human Subjects Protections Institutional Review Board | 11369 |
| University of Alabama at Birmingham | The University of Alabama at Birmingham Institutional Review Board for Human Use | FO70712014 |
| University of California, San Diego | University of California, San Diego Human Research Protections Program | 070876 |
| University of Iowa | The University of Iowa Human Subjects Office | 200710717 |
| Ann Arbor VA | VA Ann Arbor Healthcare System IRB | PCC 2008–110732 |
| University of Minnesota | University of Minnesota Research Subjects’ Protection Programs (RSPP) | 0801M24949 |
| University of Pittsburgh | University of Pittsburgh Institutional Review Board | PRO07120059 |
| University of Texas Health Sciences Center at San Antonio | UT Health Science Center San Antonio Institutional Review Board | HSC20070644H |
| Health Partners Research Foundation | Health Partners Research Foundation Institutional Review Board | 07–127 |
| University of Michigan | Medical School Institutional Review Board (IRBMED) | HUM00014973 |
| Minneapolis VA Medical Center | Minneapolis VAMC IRB | 4128-A |
| Fallon Clinic | Institutional Review Board/Research Review Committee Saint Vincent Hospital – Fallon Clinic – Fallon Community Health Plan | 1143 |